Drug intelligence / Profile preview

YHP2305

Development stage: Phase 1
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YHP2305 is Yuhan's oral **vonoprazan** generic candidate, developed as a bioequivalent version of Takeda's vonoprazan product. Vonoprazan is a small-molecule potassium-competitive acid blocker that reversibly inhibits the gastric hydrogen-potassium ATPase, suppressing gastric acid secretion. YHP2305 was evaluated against YHR2404 in a completed randomized single-dose crossover bioequivalence study in healthy adults and is intended for development in gastroesophageal reflux disease.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on YHP2305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHP2305.

Explore the full profile